One of our top priorities at Mass General Brigham is to address the gap in Innovation between discovery and clinical proof-of-concept, where many promising technologies are stranded. This is often called the valley of death, where it is estimated that for every 5,000-10,000 compounds that enter the drug discovery pipeline, only 250 will progress to pre-clinical development.  


Mass General Brigham's Innovation is 'bridging the gap' with growth opportunities for early-stage ventures within the Partners Network that provides patients with greater access to potentially life-saving and life-improving technologies. 


With the addition of TIF and AIDF to our already established Mass General Brigham's Innovation Fund, we address unmet clinical needs by increasing our translational, pre-clinical, and pre-commercial development capabilities.  This encourages more early-stage and pre-clinical development throughout the Mass General Brigham's investigator community, and in the long-term, improves the lives of our patients.

About the Translational Innovation Fund (TIF)


The Translation Innovation Fund was created in 2019 to address the funding gap between basic research or drug discovery and clinical proof-of-concept. TIF amplifies the value of pre-commercial projects prior to their commercialization. TIF-funded projects execute on a translational plan developed alongside the PI, that is operated on their behalf by TIF staff. Our focus is on discoveries with high commercial potential from the Mass General Brigham network of hospitals.

For more information on Devices & Diagnostics, please contact Erin McKenna, Operating Partner


For more information on Therapeutics, please contact Dione Kobayashi PhD, Operating Partner


About the Artificial Intelligence and Digital Translation Fund (AIDIF)


The Artificial Intelligence and Digital Innovation Fund was established in 2020 to invest in commercial stage digital health and AI based companies that address unmet needs at Mass General Brigham and are not based on technologies emerging from the health system.

A $30M fund, we work closely with the health system’s clinical, operations, research and digital leadership to identify key areas for investment focus and with Innovation’s Business Development group to identify potential co-development opportunities. We seek to co-invest with strong syndicate partners who can help these early commercial companies scale.

For more information about AIDIF, please contact Gaye Bok, Partner

Learn more about Mass General Brigham's Innovation 

Contact Us | Disclaimer Privacy Policy | Mass General Brigham Innovation